Monopar Therapeutics (MNPR) Insider Trading & Ownership $50.52 -0.81 (-1.58%) Closing price 02/12/2025 04:00 PM EasternExtended Trading$50.50 -0.02 (-0.04%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Monopar Therapeutics (NASDAQ:MNPR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage34.90%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$86,561.20Number OfInsiders Selling(Last 12 Months)0 Get MNPR Insider Trade Alerts Want to know when executives and insiders are buying or selling Monopar Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MNPR Insider Buying and Selling by Quarter Monopar Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/28/2024Karthik RadhakrishnanCFOBuy1,550$16.25$25,187.50 6/20/2024Andrew CittadineCOOBuy4,101$3.70$15,173.70 6/17/2024Andrew CittadineCOOBuy2,400$4.50$10,800.00 6/13/2024Andrew CittadineCOOBuy2,400$4.55$10,920.00 6/3/2024Andrew CittadineCOOBuy2,400$3.80$9,120.00 5/31/2024Andrew CittadineCOOBuy2,400$3.20$7,680.00 5/29/2024Andrew CittadineCOOBuy2,400$3.20$7,680.00 (Data available from 1/1/2013 forward) MNPR Insider Trading Activity - Frequently Asked Questions Who is on Monopar Therapeutics's Insider Roster? The list of insiders at Monopar Therapeutics includes Andrew Cittadine, and Karthik Radhakrishnan. Learn more on insiders at MNPR. What percentage of Monopar Therapeutics stock is owned by insiders? 34.90% of Monopar Therapeutics stock is owned by insiders. Learn more on MNPR's insider holdings. Which Monopar Therapeutics insiders have been buying company stock? The following insiders have purchased MNPR shares in the last 24 months: Andrew Cittadine ($61,373.70), and Karthik Radhakrishnan ($25,187.50). How much insider buying is happening at Monopar Therapeutics? Insiders have purchased a total of 17,651 MNPR shares in the last 24 months for a total of $86,561.20 bought. Monopar Therapeutics Key ExecutivesDr. Chandler D. Robinson M.B.A. (Age 40)M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director Compensation: $710.5kMs. Kim R. Tsuchimoto CPA (Age 61)CFO, Secretary, Treasurer & Director Compensation: $354kMr. Andrew J. Cittadine M.B.A. (Age 51)Chief Operating Officer Compensation: $416.7kDr. Patrice P. Rioux M.D. (Age 73)Ph.D., Acting Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies ANI Pharmaceuticals Insider Selling Day One Biopharmaceuticals Insider Selling Xencor Insider Selling Spyre Therapeutics Insider Selling 89bio Insider Selling Ocular Therapeutix Insider Selling Arcus Biosciences Insider Selling Aurinia Pharmaceuticals Insider Selling ARS Pharmaceuticals Insider Selling Adaptive Biotechnologies Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles META Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying3 Stocks With Strong Capital Returns and Insider Buying Signals This page (NASDAQ:MNPR) was last updated on 2/13/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.